Anti-HIV group I introns and uses thereof in treating HIV infections
US9707257B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 28, 2011 |
| Grant date | Jul 18, 2017 |
| Priority date | — |
| Expiry date | Apr 28, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.